TNSN96051A1 - Benzamides pour le traitement de degenerescences neurologiques - Google Patents

Benzamides pour le traitement de degenerescences neurologiques

Info

Publication number
TNSN96051A1
TNSN96051A1 TNTNSN96051A TNSN96051A TNSN96051A1 TN SN96051 A1 TNSN96051 A1 TN SN96051A1 TN TNSN96051 A TNTNSN96051 A TN TNSN96051A TN SN96051 A TNSN96051 A TN SN96051A TN SN96051 A1 TNSN96051 A1 TN SN96051A1
Authority
TN
Tunisia
Prior art keywords
compounds
treatment
degenerations
benzamides
neurological
Prior art date
Application number
TNTNSN96051A
Other languages
English (en)
Inventor
David Flitter William
A Garland William
L Wilcox Allan
E Paylor Richard
Original Assignee
Centaur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/415,694 external-priority patent/US5658953A/en
Priority claimed from US08/415,847 external-priority patent/US5643965A/en
Priority claimed from US08/415,248 external-priority patent/US5659082A/en
Application filed by Centaur Pharmaceuticals Inc filed Critical Centaur Pharmaceuticals Inc
Publication of TNSN96051A1 publication Critical patent/TNSN96051A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

IL EST DIVULGUE UN GROUPE DE COMPOSES BENZAMIDE QUI SONT UTILES POUR LE TRAITEMENT DE DESORDRES NEURODEGENERATFS . LES METHODES POUR LA FABRICATION DE CES COMPOSES SONT DECRITES. CES COMPOSES SONT FORMES EN COMPOSITIONS PHARMACEUTIQUES POUR ADMINISTRATION PAR VOIE BUCCALE OU INTRAVEINEUSE A DES PATIENTS SOUFFRANT D'ETATS, TELS QUE LA MALADIE DE PARKINSON OU LA MALADIE D'ALZHEIMER, CARACTERISES PAR UNE ALTERATION FONCTIONNELLE PROGRESSIVE DU SYSTEME NERVEUX CENTRAL. CES COMPOSES SONT SUSCEPTIBLES DE STOPPER OU DE RALENTIR CETTE ALTERATION PROGRESSIVE.
TNTNSN96051A 1995-04-03 1996-04-03 Benzamides pour le traitement de degenerescences neurologiques TNSN96051A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41567795A 1995-04-03 1995-04-03
US08/415,694 US5658953A (en) 1995-04-03 1995-04-03 Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders
US08/415,847 US5643965A (en) 1995-04-03 1995-04-03 Aminobenzamide compounds for the treatment of neurodegenerative disorders
US08/415,248 US5659082A (en) 1995-04-03 1995-04-03 Nitro- and aminobenzamide compounds for neurodegenerative disorders

Publications (1)

Publication Number Publication Date
TNSN96051A1 true TNSN96051A1 (fr) 2005-03-15

Family

ID=27503636

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN96051A TNSN96051A1 (fr) 1995-04-03 1996-04-03 Benzamides pour le traitement de degenerescences neurologiques

Country Status (39)

Country Link
EP (1) EP0819113B1 (fr)
JP (1) JP3479658B2 (fr)
KR (1) KR100429120B1 (fr)
CN (1) CN1073552C (fr)
AR (1) AR002978A1 (fr)
AT (1) ATE202552T1 (fr)
AU (1) AU721045B2 (fr)
BG (1) BG63384B1 (fr)
CA (1) CA2215166A1 (fr)
CO (1) CO4700431A1 (fr)
CZ (1) CZ295852B6 (fr)
DE (1) DE69613567T2 (fr)
DK (1) DK0819113T3 (fr)
DZ (1) DZ2012A1 (fr)
EA (1) EA002031B1 (fr)
EE (1) EE03437B1 (fr)
ES (1) ES2160240T3 (fr)
GR (1) GR3036466T3 (fr)
HK (1) HK1016964A1 (fr)
HR (1) HRP960156B1 (fr)
HU (1) HUP9801759A3 (fr)
IL (1) IL117629A (fr)
IS (1) IS1919B (fr)
MA (1) MA23837A1 (fr)
MX (1) MX9707596A (fr)
MY (1) MY121206A (fr)
NO (1) NO318441B1 (fr)
NZ (1) NZ306204A (fr)
PL (1) PL184121B1 (fr)
PT (1) PT819113E (fr)
RO (1) RO116190B1 (fr)
SA (1) SA96160739B1 (fr)
SI (1) SI0819113T1 (fr)
SK (1) SK282900B6 (fr)
TN (1) TNSN96051A1 (fr)
TR (1) TR199701114T1 (fr)
TW (1) TW381073B (fr)
WO (1) WO1996031462A1 (fr)
YU (1) YU21096A (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332438A (en) * 1996-04-17 2001-02-23 Centaur Pharmaceuticals Inc Use of acetamido, amino or nitro substituted benzamide derivatives for treating of dementia associated with AIDS virus (HIV-1) infection
NZ503823A (en) * 1997-10-27 2002-04-26 Sumitomo Pharma Amide derivatives and their use in treating retinal neurodegenerative disorders
AU3985699A (en) * 1998-05-19 1999-12-06 Centaur Pharmaceuticals, Inc. Amide therapeutics for the treatment of inflammatory bowel disease
EP1079820A1 (fr) 1998-05-19 2001-03-07 Centaur Pharmaceuticals, Inc. Medicament a base de benzamide, destine au traitement des affections inflammatoires de l'intestin
WO2000064430A1 (fr) * 1999-04-23 2000-11-02 Sumitomo Pharmaceuticals Co., Ltd. Inhibiteurs de l'apoptose
CN101817761B (zh) * 2010-01-29 2014-06-25 浙江大学 苯甲酸酯类衍生物及制备方法和应用
EP2535059A4 (fr) * 2010-02-10 2014-03-12 Public Univ Corp Yokohama City Utilisation d'un composé se liant à msin3b qui se lie, de façon spécifique, au facteur silenceur de la spécification neuronale nrsf
WO2014155184A1 (fr) * 2013-03-28 2014-10-02 Rhenovia Pharma Traitement pour maladie de parkinson
CN115594603A (zh) * 2022-10-09 2023-01-13 湖北师范大学（Cn） 微通道反应器制备n-叔丁基-4-氨基苯甲酰胺的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1069882B (it) * 1975-12-22 1985-03-25 Mallinckrodt Inc 3 5 bis acilammino benzammidi particolarmente utili come agenti di contrasto per raffi x e procedimento per la loro preparazione
JPS5721320A (en) * 1980-07-11 1982-02-04 Chugai Pharmaceut Co Ltd Blood sugar level depressing agent
JPS5867657A (ja) * 1981-10-15 1983-04-22 Chugai Pharmaceut Co Ltd ペンズアミド誘導体
US5472983A (en) * 1994-04-14 1995-12-05 Centaur Pharmaceuticals, Inc. Benzamide-containing pharmaceutical compositions

Also Published As

Publication number Publication date
CA2215166A1 (fr) 1996-10-10
DE69613567T2 (de) 2002-04-18
CZ309897A3 (cs) 1998-12-16
AU721045B2 (en) 2000-06-22
IS1919B (is) 2004-03-15
NZ306204A (en) 1999-01-28
EA199700287A1 (ru) 1998-04-30
KR100429120B1 (ko) 2004-08-18
DK0819113T3 (da) 2001-10-15
CN1073552C (zh) 2001-10-24
NO318441B1 (no) 2005-03-21
PL184121B1 (pl) 2002-09-30
JPH11501319A (ja) 1999-02-02
BG63384B1 (bg) 2001-12-29
DZ2012A1 (fr) 2002-07-21
MX9707596A (es) 1998-06-30
EP0819113B1 (fr) 2001-06-27
GR3036466T3 (en) 2001-11-30
TR199701114T1 (xx) 1998-02-21
BG101929A (en) 1998-04-30
SI0819113T1 (en) 2001-10-31
WO1996031462A1 (fr) 1996-10-10
PT819113E (pt) 2001-10-30
SK132597A3 (en) 1998-09-09
EE9700235A (et) 1998-04-15
HUP9801759A3 (en) 2001-06-28
SA96160739B1 (ar) 2005-10-15
AR002978A1 (es) 1998-05-27
ATE202552T1 (de) 2001-07-15
HK1016964A1 (en) 1999-11-12
CN1182416A (zh) 1998-05-20
HRP960156A2 (en) 1997-10-31
EE03437B1 (et) 2001-06-15
TW381073B (en) 2000-02-01
ES2160240T3 (es) 2001-11-01
AU5440496A (en) 1996-10-23
EP0819113A1 (fr) 1998-01-21
NO974569D0 (no) 1997-10-02
SK282900B6 (sk) 2003-01-09
EA002031B1 (ru) 2001-12-24
DE69613567D1 (de) 2001-08-02
JP3479658B2 (ja) 2003-12-15
NO974569L (no) 1997-11-21
KR19980703562A (ko) 1998-11-05
IL117629A (en) 2000-08-13
MY121206A (en) 2006-01-28
IS4569A (is) 1997-09-25
MA23837A1 (fr) 1996-12-31
PL322625A1 (en) 1998-02-02
IL117629A0 (en) 1996-07-23
YU21096A (sh) 1999-03-04
HRP960156B1 (en) 2002-04-30
HUP9801759A2 (hu) 1998-12-28
RO116190B1 (ro) 2000-11-30
CO4700431A1 (es) 1998-12-29
CZ295852B6 (cs) 2005-11-16

Similar Documents

Publication Publication Date Title
US4507323A (en) Treatment of psychosexual dysfunctions
TNSN03058A1 (fr) Derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant.
MA30252B1 (fr) Vaccin therapeutique
EP0321516A1 (fr) Derives d'acide 3-indolepyruvique et utilisation pharmaceutique desdits derives.
MA27881A1 (fr) Derives d'imidazole utilises comme antagonistes du recepteur du glutamate
BR0315283A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de doenças neurológicas ou de doenças inflamatórias do trato respiratório superior
IL112427A0 (en) Production of pharmaceutical compositions comprising anti-tnf antibodies
TNSN96051A1 (fr) Benzamides pour le traitement de degenerescences neurologiques
LV12766A (lv) Composition of l-dopa esters
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA27751A1 (fr) 4-phényltétrahydroisoquinolines substituées, procédé de production de ces composés, utilisation de ces composés en tant que médicaments et médicament contenant de tels composés
HUP0101627A2 (hu) Neuropszichiátriai rendellenességek kezelésére alkalmazható gyógyászati készítmények
HUP0204023A2 (hu) Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
TNSN01016A1 (fr) Procede pour la synthese asymetrique de pregabaline
MA26999A1 (fr) Utilisation d'agonistes inverses de gabaa en association avec des agonistes partiels des recepteurs de nicotine, un oestrogene, des modulateurs selectifs d'oestrogenes ou la vitamine e pour le traitement de troubles cognitifs
BE899564A (fr) Composition pharmaceutique pour l'administration parenterale a base de nimodipin et procede pour sa preparation.
TNSN99177A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1, 2-a] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
HUP0302333A2 (hu) Glatiramer-acetát (kopolimer 1) alkalmazása központi idegrendszeri rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
TNSN00139A1 (fr) Acides phenoxyacetiques substitues
TNSN99013A1 (fr) Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2554346B1 (fr) Ensemble et procede pour l'administration de gangliosides et de leurs derives par inhalation et compositions pharmaceutiques les contenant
MA27592A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
Weiner et al. Meige's syndrome during long-term dopaminergic therapy in Parkinson's disease